Allarity Therapeutics received a letter from Nasdaq indicating non-compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
AI Assistant
ALLARITY THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.